5 Key Takeaways

• 1

  Gene therapy for sickle cell disease could be cost-effective in Uganda if prices are significantly reduced.

• 2

  A modeling study adapted US economic data to assess gene therapy's viability in Uganda's low-income healthcare setting.

• 3

  The lifetime standard-of-care cost for sickle cell disease in Uganda is estimated at $21,877, compared to over $600,000 in the U.S.

• 4

  Casgevy is identified as the more viable gene therapy option for Uganda, meeting cost-effectiveness thresholds when local costs are applied.

• 5

  The study aims to help policymakers expand equitable access to gene therapy in regions with high disease burden and limited resources.